Logo

Invitrogen s Earnings, Sales Soar in Q4

Feb 12, 2004

NEW YORK, Feb. 12 (GenomeWeb News) - Invitrogen reported increased earnings and revenues for the fourth quarter today.

 

Revenues increased to $207.8 million, from $161.8 million during the same period the previous year. Invitrogen attributed this increase in sales mainly to products it obtained from its acquisitions of Molecular Probes, Pan Vera, and InforMax.

 

R&D expenses soared to $16.1 million, from $9.7 million during the same quarter in 2002.

 

Net income for the quarter was $12.6 million, or $.24 per share, up from $10.2 million, or $.2 per share, the year before.

 

As of Dec. 31, 2003, Invitrogen had $998.7 million in cash and investments.

 

 

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.